BioSyent Inc. (CVE:RX) Insider FAX Capital Corp. Sells 500,000 Shares of Stock

BioSyent Inc. (CVE:RX) insider FAX Capital Corp. sold 500,000 shares of the company’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of C$10.05, for a total transaction of C$5,025,000.00.

BioSyent Price Performance

RX stock opened at C$10.90 on Wednesday. The company has a quick ratio of 6.91, a current ratio of 6.13 and a debt-to-equity ratio of 3.40. The firm has a market cap of C$126.33 million, a price-to-earnings ratio of 18.17 and a beta of 0.94. The company’s fifty day simple moving average is C$10.16 and its 200 day simple moving average is C$9.29. BioSyent Inc. has a 12-month low of C$7.66 and a 12-month high of C$11.45.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.